Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

753 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Subbiah V, et al. Among authors: schellens jhm. J Clin Oncol. 2018 Jan 1;36(1):7-13. doi: 10.1200/JCO.2017.73.6785. Epub 2017 Oct 26. J Clin Oncol. 2018. PMID: 29072975 Free PMC article. Clinical Trial.
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
Raymond E, ten Bokkel Huinink WW, Taïeb J, Beijnen JH, Faivre S, Wanders J, Ravic M, Fumoleau P, Armand JP, Schellens JH; European Organization for the Research and Treatment of Cancer Early Clinical Study Group. Raymond E, et al. J Clin Oncol. 2002 Aug 15;20(16):3508-21. doi: 10.1200/JCO.2002.09.030. J Clin Oncol. 2002. PMID: 12177112 Clinical Trial.
Challenges of oral chemotherapy.
Schellens JH. Schellens JH. Clin Adv Hematol Oncol. 2005 Feb;3(2):99-100. Clin Adv Hematol Oncol. 2005. PMID: 16166975 No abstract available.
Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
Langenberg MH, van Herpen CM, De Bono J, Schellens JH, Unger C, Hoekman K, Blum HE, Fiedler W, Drevs J, Le Maulf F, Fielding A, Robertson J, Voest EE. Langenberg MH, et al. J Clin Oncol. 2009 Dec 20;27(36):6152-9. doi: 10.1200/JCO.2009.22.2273. Epub 2009 Nov 9. J Clin Oncol. 2009. PMID: 19901116 Clinical Trial.
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Langenberg MH, Witteveen PO, Roodhart JM, Verheul HM, Mergui-Roelvink M, van der Sar J, Brendel E, Laferriere N, Schellens JH, Voest EE. Langenberg MH, et al. Clin Cancer Res. 2010 Apr 1;16(7):2187-97. doi: 10.1158/1078-0432.CCR-09-2436. Epub 2010 Mar 16. Clin Cancer Res. 2010. PMID: 20233884 Clinical Trial.
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Koolen SL, Witteveen PO, Jansen RS, Langenberg MH, Kronemeijer RH, Nol A, Garcia-Ribas I, Callies S, Benhadji KA, Slapak CA, Beijnen JH, Voest EE, Schellens JH. Koolen SL, et al. Clin Cancer Res. 2011 Sep 15;17(18):6071-82. doi: 10.1158/1078-0432.CCR-11-0353. Epub 2011 Jul 13. Clin Cancer Res. 2011. PMID: 21753156 Clinical Trial.
753 results